CHICAGO, IL – The American Medical Association (AMA), in a surprising move, has officially rescinded a previous statement against the use of Hydroxychloroquine (HCQ) in the treatment of COVID-19 patients, giving physicians the okay to return to utilizing the medication at their discretion.
Previously, the AMA had issued a statement in March that was highly critical of HCQ in regards to its use as a proposed treatment by some physicians in the early stages of COVID-19. In addition to discouraging doctors from ordering the medication in bulk for “off-label” use – HCQ is typically used to treat diseases such as malaria – they also claimed that there was no proof that it was effective in treating COVID, and that its use could be harmful in some instances.
However, on page 18 of a recent AMA memo, issued on October 30, (resolution 509, page 3) the organization officially reversed their stance on HCQ, stating that its potential for good currently may supersede the threat of any potential harmful side effects.
So, there we have it. HCQ could not be approved before the election, because President Trump had recommended it. Meanwhile, with an 8o +% reduced risk of having to be admitted to the hospital if administered with Azithromycin and Zinc as soon as testing positive or symptoms occurred, many (70000+) lives could have been saved.
It has come to my attention that the resolution, while adopted got stopped before a new and valid recommendation was issued. There are powerful interests in the AMA that want to keep things as they are rather than advance real medical science based on real results, and never admit a mistake. Meanwhile, people are dying because of lack of solid, but inexpensive medical solutions.
The recommendation is still up on their website, but should it disappear, here it is , the important part part.
RESOLVED, That our American Medical Association rescind its statement calling for physicians to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence becomes available to conclusively illustrate that the harm associated with use outweighs benefit early in the disease course. Implying that such treatment is inappropriate contradicts AMA Policy H-120.988, “Patient Access to Treatments Prescribed by Their Physicians,” that addresses off label prescriptions as appropriate in the judgement of the prescribing physician (Directive to Take Action); and be it further
RESOLVED, That our AMA rescind its joint statement with the American Pharmacists Association and American Society of Health System Pharmacists, and update it with a joint statement notifying patients that further studies are ongoing to clarify any potential benefit of hydroxychloroquine and combination therapies for the treatment of COVID-19 (Directive to Take Action); and be it further
RESOLVED, That our AMA reassure the patients whose physicians are prescribing 18 hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by issuing an updated statement clarifying our support for a physician’s ability to prescribe an FDA-approved medication for off label use, if it is in her/his best clinical judgement, with specific reference to the use of hydroxychloroquine and combination therapies for the treatment of the earliest stage of COVID-19 (Directive to Take Action); and be it further….
(NOQ REPORT and LEN BILEN’S BLOG)